ContraFect Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor ContraFect te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	09 Nov 2023

Recente toekomstige groei-updates

Recent updates

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

Mar 09

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Jan 15

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Nov 24

Contrafect EPS beats by $0.16

Nov 13

Winst- en omzetgroeiprognoses

OTCPK:CFRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
9/30/2023	N/A	-24	-36	-36	N/A
6/30/2023	N/A	-36	-37	-37	N/A
3/31/2023	N/A	-46	-43	-43	N/A
12/31/2022	N/A	-65	-46	-46	N/A
9/30/2022	N/A	-60	-45	-45	N/A
6/30/2022	N/A	-48	-46	-46	N/A
3/31/2022	N/A	-35	-44	-44	N/A
12/31/2021	N/A	-20	-41	-41	N/A
9/30/2021	N/A	-22	-40	-40	N/A
6/30/2021	N/A	-14	-37	-37	N/A
3/31/2021	N/A	-26	-35	-35	N/A
12/31/2020	N/A	-28	-33	-33	N/A
9/30/2020	N/A	-32	-33	-33	N/A
6/30/2020	N/A	-41	-29	-29	N/A
3/31/2020	N/A	-32	-28	-28	N/A
12/31/2019	N/A	-13	-27	-27	N/A
9/30/2019	N/A	3	-27	-27	N/A
6/30/2019	N/A	4	-29	-29	N/A
3/31/2019	N/A	-7	-27	-27	N/A
12/31/2018	N/A	-38	-26	-26	N/A
9/30/2018	N/A	-48	-25	-25	N/A
6/30/2018	N/A	-46	-25	-25	N/A
3/31/2018	N/A	-28	-25	-25	N/A
12/31/2017	N/A	-16	-25	-25	N/A
9/30/2017	N/A	-10	-27	-27	N/A
6/30/2017	N/A	-19	N/A	-29	N/A
3/31/2017	N/A	-26	N/A	-29	N/A
12/31/2016	N/A	-29	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-27	N/A
6/30/2016	N/A	-32	N/A	-25	N/A
3/31/2016	N/A	-29	N/A	-24	N/A
12/31/2015	N/A	-25	N/A	-22	N/A
9/30/2015	N/A	-22	N/A	-20	N/A
6/30/2015	N/A	-33	N/A	-20	N/A
3/31/2015	N/A	-34	N/A	-17	N/A
12/31/2014	N/A	-35	N/A	-15	N/A
9/30/2014	N/A	-41	N/A	-14	N/A
6/30/2014	N/A	-29	N/A	-12	N/A
3/31/2014	N/A	-24	N/A	-13	N/A
12/31/2013	N/A	-24	N/A	-14	N/A
9/30/2013	N/A	-19	N/A	-15	N/A
6/30/2013	N/A	-20	N/A	-16	N/A
3/31/2013	N/A	-20	N/A	-17	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van CFRX boven de spaarquote ( 2.2% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van CFRX naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van CFRX naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van CFRX naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat CFRX volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CFRX naar verwachting over 3 jaar hoog zal zijn

ContraFect Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$2.00

No longer forecast to breakeven

Price target decreased to US$13.00

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Recent updates

ContraFect Corporation Filed for Bankruptcy

ContraFect Corporation Announces Chief Executive Officer Changes

ContraFect Receives Determination Letter from the Nasdaq Hearings Advisor to Delist its Common Stock from the Nasdaq Capital Market

ContraFect Receives Non Compliance Notice from Nasdaq

Nasdaq Determines to Delist ContraFect's Common Stock from The Nasdaq Capital Market Due to Non-Compliance with Minimum Stockholders' Equity Requirement

ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens

ContraFect Announces Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Nasdaq Determines to Deny ContraFect's Request for Continued Listing on the Nasdaq Capital Market

ContraFect Corporation Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

ContraFect Corporation Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Price target decreased to US$2.00

ContraFect Receives Non-Compliance Letter from Nasdaq

Contrafect Corporation Announces Resignation of Cara Cassino as Chief Medical Officer and Executive Vice President of Research and Development

Contrafect GAAP EPS of -$0.46 misses by $0.13

No longer forecast to breakeven

Contrafect Announces Independent Dsmb Recommends Exebacase Phase 3 Disrupt Study Be Stopped for Futility Following Interim Analysis

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$13.00

ContraFect Corporation, Annual General Meeting, May 17, 2022

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Price target decreased to US$15.90

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

ContraFect Corporation Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

New 90-day low: US$4.81

ContraFect Corporation Appoints Jane F. Barlow to its Board of Directors

New 90-day low: US$4.96

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

New 90-day low: US$5.09

New 90-day high: US$5.87

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Contrafect EPS beats by $0.16

Analysts update estimates

ContraFect Corporation announced that it has received $3 million in funding from Pfizer Inc.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven